HIV seropositivity in squamous cell carcinoma of the head and neck (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

HIV seropositivity in squamous cell carcinoma of the head and neck (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 14:A880 1995. Unique Identifier : AIDSLINE ICDB/95614032
Mannancheril A; Gordon T; Shum J; Savona S; Department of Medicine, New York Medical College, Lincoln; Hospital, Bronx, NY 10451

Abstract: Lincoln Hospital is a 584 bed acute care municipal hospital in the South Bronx where the AIDS prevalence rate is 1.2 per 100 adults compared with 0.6 per 100 adults as a New York City average. It has the highest heterosexual and intravenous drug use (IVDU) rate in New York City. In the 18 month period from January 1993 to June 1994, 18 cases of squamous cell carcinoma (SCC) of the head and neck were treated. There were 16 men and 2 women. Ten patients were tested for HIV, two refused testing and 6 were not offered testing. Eleven patients denied risk factors for HIV infection; seven admitted risk factors of IVDU and heterosexual intercourse with IVDU persons. All patients with SCC had cigarette exposure of greater than 20 packs-year and significant ethanol usage. Four of ten patients tested were HIV positive (40%; 22% of the entire SCC group including those not tested). Both women with SCC were HIV positive. The average age in the HIV positive group was 40; the HIV negative group was 58. All HIV positive patients presented with T3 or T4 lesions; 90% of HIV negative patients presented with T3 or T4 lesions. One of four HIV positive patient received chemotherapy of cisplatin 80 mg/m2 and 5-Fu 600 mg/m2 x 5d. The mean survival of the HIV positive patients from the time of diagnosis of SCC was 4 months. The mean survival of the HIV negative patients has not been reached and is greater than 1 year. In contrast to SCC no cases of HIV seropositivity were noted in 7 thyroid carcinomas, 2 undifferentiated nasopharyngeal carcinomas, 2 mucoepidermoid carcinomas, 1 adenosquamous carcinoma and 1 ameloblastoma. HIV seropositivity should predict a poor outcome in rapidly progressing SCC of the head and neck; the lifestyle of patient at risk for SCC may lead to HIV seropositivity in our community. HIV seropositivity should be strongly suspected in young female patients with SCC of the head and neck.

Keywords: Adult Carcinoma, Squamous Cell/*COMPLICATIONS/DRUG THERAPY Female Head and Neck Neoplasms/*COMPLICATIONS/DRUG THERAPY Human HIV Seropositivity/*COMPLICATIONS Male ABSTRACT
951230
M95C3216

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .